Dulaglutide may reduce stroke in T2D
31 Jan 2020
bởiRoshini Claire Anthony
The GLP-1 receptor agonist* dulaglutide may reduce the incidence of stroke, particularly ischaemic stroke, in individuals with type 2 diabetes (T2D) and cardiovascular (CV) risk factors, according to findings of an exploratory analysis of the REWIND** trial.